Impaired Cerebral Vasoreactivity Despite Symptom Resolution in Sports-Related Concussion

Traumatic brain injury (TBI) is associated with increased risk of later-life neurodegeneration and dementia. However, the underpinning mechanisms are poorly understood, and secondary injury resulting from perturbed physiological processes plays a significant role. Cerebral vasoreactivity (CVR), a me...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of neurotrauma 2019-08, Vol.36 (16), p.2385-2390
Hauptverfasser: Purkayastha, Sushmita, Sorond, Farzaneh A, Lyng, Sydney, Frantz, Justin, Murphy, Megan N, Hynan, Linda S, Sabo, Tonia, Bell, Kathleen R
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Traumatic brain injury (TBI) is associated with increased risk of later-life neurodegeneration and dementia. However, the underpinning mechanisms are poorly understood, and secondary injury resulting from perturbed physiological processes plays a significant role. Cerebral vasoreactivity (CVR), a measure of hemodynamic reserve, is known to be impaired in TBI. However, the temporal course of this physiological perturbation is not established. We examined CVR and clinical symptoms on day 3 (T1), day 21 (T2), and day 90 (T3) after concussion in collegiate athletes and cross-sectionally in non-injured controls. Changes in middle cerebral artery blood flow velocity (MCAV; transcranial Doppler ultrasonography) were measured during changes in end-tidal CO (PetCO ) at normocapnia, hypercapnia (inspiring 8% CO ), and hypocapnia (hyperventilation). CVR was determined as the slope of the linear relationship and expressed as percent change in MCAV per mmHg change in PetCO . CVR was attenuated during the acute phase T1 (1.8 ± 0.4U;  = 0.0001), subacute phases T2 (2.0 ± 0.4U;  = 0.0017), and T3 (1.9 ± 0.6U;  = 0.023) post-concussion compared to the controls (2.3 ± 0.3U). Concussed athletes exhibited higher symptom number (2.5 ± 3.0 vs. 12.1 ± 7.0;  
ISSN:0897-7151
1557-9042
DOI:10.1089/neu.2018.5861